T cell ex­perts at Kiadis bag Cy­toSen's NK cell tech, plot­ting a dual can­cer killing ap­proach with tips from Carl June

7 years ago
Deals

Lon­don list­ed PureTech Health joins forces with ninth big phar­ma part­ner — Boehringer In­gel­heim

7 years ago
R&D

Rev­enue plunges, stock takes a drub­bing, but Te­va CEO Kåre Schultz still grabs $32.5M in chart-top­ping com­pen­sa­tion

7 years ago
People

NICE backs Akcea's Tegse­di; EMA re­stricts Lem­tra­da use while it probes safe­ty con­cerns

7 years ago
News Briefing

Chi­nese phar­ma­ceu­ti­cal man­u­fac­tur­er in spot­light af­ter weld­ing ac­ci­dent kills 10

7 years ago
China

Months af­ter Re­gen­eron se­cured FDA ap­proval for 12-week Eylea reg­i­men, No­var­tis buys speedy US re­view for its ri­val

7 years ago
R&D

Achao­gen’s bank­rupt­cy and go­ing-out-of-busi­ness sale of­fer a grim cau­tion­ary tale for the fu­ture of an­tibi­ot­ic ...

7 years ago
Financing
Startups

In­dus­try calls for changes in two REMS guid­ances

7 years ago
Pharma

For­get biosim­i­lars. Pe­ter Bach and Mark Trusheim be­lieve price con­trols are the bet­ter way to rein in bi­o­log­ics ...

7 years ago
People
Pharma

Flag­ship un­veils gut-fo­cused up­start Kin­tai, with for­mer GSK ex­ec as chief

7 years ago
Financing
Startups

With $150M and a new NASH dis­cov­ery deal with Gilead, AI star Daphne Koller has set out to change the drug R&D world

7 years ago
People
Financing

Am­gen prices bone builder Eveni­ty at $21,900/year to com­pete on con­ve­nience, not cost

7 years ago
Pharma

SCO­TUS just turned its back on Al­ler­gan’s le­gal ma­neu­ver to take a blow at in­ter partes re­view. What did you ...

7 years ago
Bioregnum
Opinion

Ad­verum Bio of­fers a late no­ti­fi­ca­tion about FDA hold on lead gene ther­a­py for wet AMD

7 years ago
Cell/Gene Tx

In­sys pro­motes CFO to the helm as Saeed Mo­ta­hari hits the ex­it; Gele­sis gets OK to mar­ket weight loss treat­ment

7 years ago
News Briefing

Fi­bro­cell Sci­ence sees light at the end of the tun­nel with Cas­tle Creek deal to de­vel­op 'but­ter­fly' dis­ease gene ...

7 years ago
Cell/Gene Tx

Four biotech Nas­daq wannabes out­line IPO plans — and don't miss Chi-Med's HKEX pitch

7 years ago
Financing

In­flu­en­tial proxy firms kick back at ac­tivists’ de­mands for Brent Saun­ders to give up his chair­man’s ti­tle at ...

7 years ago
People

Road war­rior: Hal Bar­ron's glob­al R&D cru­sade at GSK comes with a hefty $800,000-plus trav­el bud­get

7 years ago
People

This ven­ture play­er is plot­ting $200M in new biotech in­vest­ing — and they’re dou­bling down on a start­up-rich ...

7 years ago
Financing

Ahead of US gene ther­a­py ex­plo­sion, big con­tract drug man­u­fac­tur­er Catal­ent makes $1.2 bil­lion bet on Paragon ...

7 years ago
Deals
Outsourcing

Out­rac­ing 2 gi­ant ri­vals, J&J touts promis­ing PhI­II In­vokana da­ta as a game-chang­er for kid­ney dis­ease risks

7 years ago
R&D

Al­ny­lam spot­lights just how good the ef­fi­ca­cy da­ta are for givosir­an — tamp­ing down on safe­ty con­cerns

7 years ago
Startups
R&D

Clo­vis shut­ters PhII Rubra­ca study af­ter da­ta mon­i­tors turn thumbs down on ef­fi­ca­cy

7 years ago
R&D
First page Previous page 942943944945946947948 Next page Last page
A service from the Financial Times